These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 17261926

  • 1. Is inflammation the link between atherosclerosis and vascular calcification in chronic kidney disease?
    Tsirpanlis G.
    Blood Purif; 2007; 25(2):179-82. PubMed ID: 17261926
    [Abstract] [Full Text] [Related]

  • 2. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    D'Amelio P, Isaia G, Isaia GC.
    J Endocrinol Invest; 2009; 32(4 Suppl):6-9. PubMed ID: 19724159
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Inhibitors of vascular calcification as potential therapeutic targets.
    Rezg R, Barreto FC, Barreto DV, Liabeuf S, Drüeke TB, Massy ZA.
    J Nephrol; 2011; 24(4):416-27. PubMed ID: 21688249
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Bone and calcium update; diagnosis and therapy of bone metabolism disease update. Calcification of atherosclerotic plaques: mechanism and clinical significance].
    Kurabayashi M.
    Clin Calcium; 2011 Dec; 21(12):43-50. PubMed ID: 22133823
    [Abstract] [Full Text] [Related]

  • 8. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity.
    Venuraju SM, Yerramasu A, Corder R, Lahiri A.
    J Am Coll Cardiol; 2010 May 11; 55(19):2049-61. PubMed ID: 20447527
    [Abstract] [Full Text] [Related]

  • 9. Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis.
    Raggi P, Giachelli C, Bellasi A.
    Nat Clin Pract Cardiovasc Med; 2007 Jan 11; 4(1):26-33. PubMed ID: 17180147
    [Abstract] [Full Text] [Related]

  • 10. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD).
    Moe SM, Reslerova M, Ketteler M, O'neill K, Duan D, Koczman J, Westenfeld R, Jahnen-Dechent W, Chen NX.
    Kidney Int; 2005 Jun 11; 67(6):2295-304. PubMed ID: 15882271
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Vascular calcification: types and mechanisms].
    Valdivielso JM.
    Nefrologia; 2011 Jun 11; 31(2):142-7. PubMed ID: 21461006
    [Abstract] [Full Text] [Related]

  • 13. Arteriosclerosis, calcium phosphate deposition and cardiovascular disease in uremia: current concepts at the bench.
    El-Abbadi M, Giachelli CM.
    Curr Opin Nephrol Hypertens; 2005 Nov 11; 14(6):519-24. PubMed ID: 16205469
    [Abstract] [Full Text] [Related]

  • 14. Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis.
    Bezerra MC, Calomeni GD, Caparbo VF, Gebrim ES, Rocha MS, Pereira RM.
    Rheumatology (Oxford); 2005 Dec 11; 44(12):1503-6. PubMed ID: 16219645
    [Abstract] [Full Text] [Related]

  • 15. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.
    Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, López-Ongil S, Coll B, Fernandez E, Valdivielso JM.
    Circ Res; 2009 May 08; 104(9):1041-8. PubMed ID: 19325147
    [Abstract] [Full Text] [Related]

  • 16. Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on fetuin-A in chronic kidney disease.
    Suliman ME, García-López E, Anderstam B, Lindholm B, Stenvinkel P.
    Adv Clin Chem; 2008 May 08; 46():217-62. PubMed ID: 19004191
    [Abstract] [Full Text] [Related]

  • 17. Receptor activator of nuclear factor kappa B ligand/osteoprotegerin pathway is a promising target to reduce atherosclerotic plaque calcification.
    Quercioli A, Luciano Viviani G, Dallegri F, Mach F, Montecucco F.
    Crit Pathw Cardiol; 2010 Dec 08; 9(4):227-30. PubMed ID: 21119343
    [Abstract] [Full Text] [Related]

  • 18. [Molecular mechanisms of vascular calcification].
    Shioi A.
    Clin Calcium; 2010 Nov 08; 20(11):1611-9. PubMed ID: 21037380
    [Abstract] [Full Text] [Related]

  • 19. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification.
    Osako MK, Nakagami H, Koibuchi N, Shimizu H, Nakagami F, Koriyama H, Shimamura M, Miyake T, Rakugi H, Morishita R.
    Circ Res; 2010 Aug 20; 107(4):466-75. PubMed ID: 20595654
    [Abstract] [Full Text] [Related]

  • 20. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G.
    Expert Rev Cardiovasc Ther; 2006 Nov 20; 4(6):801-11. PubMed ID: 17173497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.